Centaurus Financial’s Sage Therapeutics SAGE Stock Holding History

Centaurus Financial’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-20	Closed	-$3K	–	1746
2018 Q2	$3K	Buy	+20	New	+$3.14K	﹤0.01%	1949

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Centaurus Financial's SAGE Position: Q3 2018 in Review

Centaurus Financial sold out of Sage Therapeutics (SAGE) in Q3 2018, closing a stake of 20 shares — an estimated $3K sold.

Centaurus Financial first reported a position in SAGE in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 275 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

Centaurus Financial reported no remaining Sage Therapeutics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 20 Sage Therapeutics shares in Q3 2018, an estimated $3K.
Centaurus Financial first reported a position in Sage Therapeutics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Sage Therapeutics position peaked at $3K in Q2 2018.
275 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.